CoChat
Sign Up
Cited by 897Parkinson's Disease Mechanisms and TreatmentsInflammasome and immune disordersNeuroinflammation and Neurodegeneration Mechanisms

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Open access
Gordon, Richard, Albornoz, Eduardo A., Christie, Daniel C., Langley, Monica R., Kumar, Vinod, Mantovani, Susanna, Robertson, Avril A. B., Butler, Mark S. +6 more·2018·Science Translational Medicine
DOI 10.1126/scitranslmed.aah4066PMC PMC6483075
Open this paper in CoChat — free account

Abstract

Oral treatment with a brain-penetrant NLRP3 inhibitor has protective effects in preclinical models of Parkinson’s disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aah4066

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MCC950, a specific NLRP3 inhibitor, showed therapeutic effect in many neurodegenerative animal models.

    “Indeed, MCC950, a specific NLRP3 inhibitor, showed therapeutic effect in many neurodegenerative animal models.355,356”

    From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [356]

    The Discussion describes MCC950 as a highly selective NLRP3 inhibitor, and the Results report neuroprotective effects in mouse models of Parkinson’s disease. The paper supports therapeutic effects in multiple Parkinson’s disease models, but not the broader claim of effects across many neurodegenerative animal models. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. [1]Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE, Parkinson disease. Nat Rev Dis Primers 3, 17013 (2017). 28332488
  2. [3]Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949– 953 (2012). 23161999 PMC3552321
  3. [4]Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G, Missing pieces in the Parkinson’s disease puzzle. Nat Med 16, 653– 661 (2010). 20495568
  4. [5]Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V, alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340– 344 (2015). 26061766
  5. [6]Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM, Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57– 71 (2011). 21982369 PMC3204802
  6. [7]Wong YC, Krainc D, alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23, 1– 13 (2017). PMC8480197 28170377
  7. [8]Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ, In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21, 404– 412 (2006). 16182554
  8. [9]Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P, Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neurosci Lett 202, 17– 20 (1995). 8787820
  9. [10]Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M, Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5, 113– 139 (2013). 23506036 PMC3639751
  10. [11]Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, Lopez-Gonzalez MJ, Dovero S, Dehay B, Normand E, Vila M, Favereaux A, Georges F, Lo Bianco C, Bezard E, Fernagut PO, Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Hum Mol Genet 26, 2603– 2615 (2017). 28520872
  11. [14]Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM, Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28, 7687– 7698 (2008). 18650345 PMC2702093
  12. [15]Vroon A, Drukarch B, Bol JG, Cras P, Breve JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM, Neuroinflammation in Parkinson’s patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42, 762– 771 (2007). 17592750
  13. [17]Schroder K, Zhou R, Tschopp J, The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296– 300 (2010). 20075245
  14. [20]Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz S, Santarelli F, Kummer MP, Griep A, Gelpi E, Beilharz M, Riedel D, Golenbock DT, Geyer M, Walter J, Latz E, Heneka MT, Microglia-derived ASC specks cross-seed amyloid-beta in Alzheimer’s disease. Nature 552, 355– 361 (2017). 29293211
  15. [22]Zhou Y, Lu M, Du RH, Qiao C, Jiang CY, Zhang KZ, Ding JH, Hu G, MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol Neurodegener 11, 28 (2016). 27084336 PMC4833896
  16. [23]Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T, Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180, 147– 150 (1994). 7700568
  17. [24]Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR, Global PDGEC, PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2, 52ra73 (2010). PMC3129986 20926834
  18. [26]Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, Brenker C, Nordhoff M, Mirandola SR, Al-Amoudi A, Mangan MS, Zimmer S, Monks BG, Fricke M, Schmidt RE, Espevik T, Jones B, Jarnicki AG, Hansbro PM, Busto P, Marshak-Rothstein A, Hornemann S, Aguzzi A, Kastenmuller W, Latz E, The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol 15, 727– 737 (2014). 24952505 PMC4116676
  19. [27]Tschopp J, Schroder K, NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10, 210– 215 (2010). 20168318
  20. [28]Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, Ghetti B, Koller BH, LeBlanc AC, Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ 22, 1676– 1686 (2015). 25744023 PMC4563782
  21. [29]Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, Rainone V, Nemni R, Mancuso R, Clerici M, The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease. Mol Neurodegener 11, 23 (2016). 26939933 PMC4778358
  22. [31]Heuer A, Smith GA, Lelos MJ, Lane EL, Dunnett SB, Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behav Brain Res 228, 30– 43 (2012). 22146593
  23. [32]Rey NL, Steiner JA, Maroof N, Luk KC, Madaj Z, Trojanowski JQ, Lee VM, Brundin P, Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease. J Exp Med 213, 1759– 1778 (2016). 27503075 PMC4995088
  24. [34]Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985– 989 (2000). 11062131
  25. [35]Beal MF, Parkinson’s disease: a model dilemma. Nature 466, S8– 10 (2010). 20739935
  26. [36]Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, Eggler J, Griffiths R, Dombroski MA, Gabel CA, Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther 299, 187– 197 (2001). 11561079
  27. [39]Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB, Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol 26, 878– 895 (2013). 23611293 PMC3685188

Cited by

Sorted by citations

Authors
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., Kanthasamy, A. G., Schroder, K., Cooper, M. A., & Woodruff, T. M.
Affiliations
  • The University of Queensland (AU)
  • Iowa State University (US)
  • Macquarie University (AU)
  • School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Dublin 2, Ireland.
Corresponding author
  • Cooper, Matthew A.
  • Woodruff, Trent M.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2018-10-31
Volume
10
Issue
465
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.aah4066
PMC
PMC6483075
OpenAlex
W2899031631
Cited by
897
References
10
Citations by year
2026: 106 · 2025: 100 · 2024: 129 · 2023: 115 · 2022: 124 · 2021: 132 · 2020: 121 · 2019: 63 · 2018: 7
FWCI
54.84
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Michael J. Fox Foundation for Parkinson’s Research (9916, 12626)
  • Australian Research Council (FT130100361)
  • National Health and Medical Research Council (1086786, 1105420)
  • Department of Science, Information Technology and Innovation, Queensland Government (AQRF03116)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Parkinson's disease, NLRP3 inflammasome, alpha-synuclein, dopaminergic neuron loss, microglial neuroinflammation, MCC950, caspase-1, ASC, IL-1β, substantia nigra, Lewy bodies, pyroptosis, disease-modifying therapy
MeSH terms
Pyroptosis, NLR Family, Pyrin Domain-Containing 3 Protein, Administration, Oral, Animals, Disease Models, Animal, Extracellular Space, Furans, Heterocyclic Compounds, 4 or More Rings, Humans, Indenes, Nerve Degeneration, Parkinson Disease, Substantia Nigra, Sulfonamides, Sulfones, Microglia, Mice, alpha-Synuclein, CARD Signaling Adaptor Proteins, Inflammasomes, Dopaminergic Neurons, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review